News >

Expert Assesses Immunotherapy Advances in Kidney Cancer

Allie Strickler @Alliejayes
Published: Tuesday, Oct 18, 2016

David McDermott, MD

David McDermott, MD

Immunotherapy is at the forefront of the burgeoning treatment landscape in renal cell carincoma (RCC), according to David McDermott, MD.

For example, the FDA approved nivolumab (Opdivo) in November 2015 as a treatment for patients with metastatic RCC following prior antiangiogenic therapy. The approval was based on the phase III CheckMate-025 trial, in which nivolumab reduced the risk of death by 27% versus everolimus (Afinitor) in this setting.

As ongoing trials continue to evaluate nivolumab and other immunotherapies in RCC, oncologists are striving to tailor treatments to the right patient populations.

“We’re always trying to improve our selection of patients, coming up with predictive markers to identify who might benefit before we start any treatment,” said McDermott.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication